Y.S.H. Business Summary

YungShin Global Holding Corp. (3705.TW), commonly referred to as Y.S.H., operates as a premier investment holding company specializing in the integrated pharmaceutical value chain. The company generates revenue primarily through the manufacture and global distribution of generic human pharmaceuticals, active pharmaceutical ingredients (APIs), animal health products, and nutritional supplements. Its business model is built on vertical integration, spanning from R&D and chemical synthesis at subsidiaries like Yung Zip Chemical to large-scale manufacturing and international sales via entities such as Yung Shin Pharmaceutical and Carlsbad Technology. As of March 2026, the group maintains a dominant market position in Taiwan while expanding its footprint across the United States, China, Japan, and Southeast Asia. Within the competitive landscape, Y.S.H. contends with major regional players such as Lotus Pharmaceutical (1795.TW), Standard Chemical & Pharmaceutical (1720.TW), and Sinphar Pharmaceutical (1734.TW), distinguishing itself as Taiwan’s largest domestic healthcare group by leveraging its extensive portfolio of over 1,000 licensed products and a robust supply chain. The leadership of Y.S.H. is anchored by the legacy of its founder, Lee Tien-te, who established the core pharmaceutical business in 1952. The current executive team is led by Chairman Fang-Hsin Lee (Dato' Dr. Lee Fang Hsin), who brings extensive experience in international market expansion and mergers and acquisitions, and President (CEO) Chih-Wei Chien, who assumed the role in August 2023 following a successful tenure in business development and operations. Supporting the core leadership are Vice Chairman Ling-Chin Lee and Financial Officer Yu-Yi Lee, ensuring continuity within the founding family’s strategic vision. The board of directors is characterized by high stability and deep industry expertise, featuring long-standing members such as Fang-Yu Lee and Fang-Chen Lee. This seasoned management team is credited with transitioning the company from a local manufacturer into a diversified global holding entity, maintaining a conservative yet growth-oriented capital structure that appeals to institutional investors focused on the healthcare sector.